BiotechTube

Rabeprazole ER + Ranitidine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux Disease (GERD)

Conditions

Gastroesophageal Reflux Disease (GERD)

Trial Timeline

Aug 31, 2008 → Dec 31, 2009

NCT ID
NCT00838526

About Rabeprazole ER + Ranitidine

Rabeprazole ER + Ranitidine is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00838526. Target conditions include Gastroesophageal Reflux Disease (GERD).

What happened to similar drugs?

4 of 20 similar drugs in Gastroesophageal Reflux Disease (GERD) were approved

Approved (4) Terminated (1) Active (16)
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄E3810 + E3810 + PlaceboEisaiPhase 3
🔄Rabeprazole ER + RanitidineEisaiPhase 3
✅rabeprazole and pantoprazoleEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00838526Phase 3Completed
NCT00839306Phase 3Completed

Competing Products

20 competing products in Gastroesophageal Reflux Disease (GERD)

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40